



Assessment of a Patient-Centric Web Application Tool for Potential Adverse Events of Oral Corticosteroids

Valliant SN¹, Sadatsafavi M², Picton-March A³, Barazetti-Scot J³, Chase K⁴, Kerr W⁵, Alfonso-Cristancho R¹

¹Global Value Evidence and Outcomes, GSK, Collegeville, PA, USA; ²NAPTIA Consultation, North Vancouver, BC, Canada; ³Human8, Manchester, UK; ⁴Human8, London, UK; ⁵Global Medical Affairs, Specialty Care, Brentford, Middlesex, UK

Background

- OCS are frequently used in patients with severe asthma and uncontrolled symptoms, either as long-term maintenance therapy, or as rescue therapy for acute symptomatic exacerbations^{1,2}
- Even short- and/or low-dose OCS treatment courses are associated with increased risk of adverse effects,³⁻⁵ emphasizing the need to reduce exposure to OCS therapies via increased awareness⁶
- Tools that increase patient awareness through a shared decision-making process may increase patient education by communicating OCS exposure risk


Conclusions

- Most patients found the tool on OCS risk **simple to use**, and the information provided considered **valuable**, **trustworthy**, and **new** for over three-quarters of participants
- More than **two-thirds** of participants would use the information from the tool to have discussions with their HCP, and therefore **may assist with shared decision-making**
- Providing context on the purpose of the tool and information on adverse outcomes, and more nuanced risk scoring based on a variety of patient characteristics may improve tool utility
- Future developments should investigate creating a tool to communicate **absolute risk** of OCS
- Overall, these **results** suggest that this online web application, following further improvements, will be **useful for raising awareness of OCS risk and informing shared decision-making** and identifies a potential unmet need for online tools to support patient decision-making

Aims




Methods



Results

N=26 Patients with current or prior exposure to OCS who completed the online survey*

*Total respondent results may not equal 100% due to rounding calculations.



Abbreviations

AE, adverse event; HCP, healthcare professional; ICS, inhaled corticosteroid; LABA, long-acting β_2 -agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist; OCS, oral corticosteroid.

References

- Fokkens WJ et al. *Rhinology* 2020;58:82–111.
- Global Strategy for Asthma Management and Prevention. 2023. Available from <https://ginasthma.org/wp-content/uploads/2023/05/GINA-2023-Full-Report-2023-WMS.pdf>.
- Bleecker ER et al. *Am J Respir Crit Care Med* 2020; 201:276–93.
- Price DB et al. *J Asthma Allergy* 2018;11:193–204.
- Sullivan PW et al. *J Allergy Clin Immunol* 2018;141:110–6.e7.
- Haughney J et al. *Adv Ther* 2023;40:2577–94.

Acknowledgments

This study was funded by GSK (GSK ID 220116). Editorial support (in the form of writing assistance, including preparation of the draft poster under the direction and guidance of the authors, collating and incorporating authors' comments for each draft, assembling tables and figures, grammatical editing and referencing) was provided by Benjamin Danet, PhD, at Fishawack Indicia (part of Avalere Health) and was funded by GSK.

Disclosures

SNV is a university worker employed by GSK. MS is an employee of NAPTIA Consultation, which received funding from GSK for conducting the study. AP-M, JB-S, and KC are employees of Human8, which received funding from GSK for conducting the study. WK and RA-C are employees of GSK and hold stocks/shares in GSK.